ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1896

Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study

Juan-Pablo Zertuche1, Gabriela Rabasa1, Alice H. Lichtenstein2, Nirupa R. Matthan2, Michael Nevitt3, James Torner4, Cora E. Lewis5, Devyani Misra6 and David Felson1, 1Boston University, Boston, MA, 2Tufts University, Boston, MA, 3University of California at San Francisco, Orinda, CA, 4University of Iowa, Iowa City, IA, 5University of Alabama at Birmingham, Birmingham, AL, 6Beth Israel Deconess Medical Center, Boston, MA

Meeting: ACR Convergence 2022

Keywords: diet, nutrition, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Osteoarthritis – Clinical Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Whole grains, particularly wheat, are an important source of dietary fiber in the US. By providing a fermentable source, whole grains can modify the gut microbiome preventing and improving dysbiosis, and have been reported to protect against chronic disease, including incident symptomatic OA and worsening knee pain.

Alkylresorcinol (AR) (1,3-dihydroxy-5-n-alkylbenzene) is a phenolic lipid with five homologues (C17:0, C19:0, C21:0, C23:0, C25:0) found in high amounts in most whole grains. Plasma AR concentrations remain stable up to 3.9 years, making it a good biomarker of long-term whole grain intake. Biomarkers, as a proxy of dietary intake, can overcome misclassification of dietary exposure base on self-reported dietary intake.

We examined whether fasting AR levels of the predominant AR homologues (C19:0, C21:0), as well as the sum of C17:0 through C25:0, were associated with the development of OA.

Methods: Participants from the Multicenter Osteoarthritis study (MOST) at risk of developing or with knee OA were studied. Knee x-rays and knee symptoms were assessed at baseline and through a 60-month follow-up period. Aliquots of plasma stored at -80°C from the baseline visit were analyzed for AR homologues and total AR using an established (UPLC-QTOF-MS) method.

We carried out two nested case-control studies using risk-set sampling, one for incident radiographic OA (new onset KL >= grade 2) and one for incident symptomatic OA (combination of knee pain on most days + radiographic OA) and examined the relationship between baseline plasma ARs and incident OA at 60 months. Given individual’s changing diets, we also tested baseline AR levels with 30-month OA outcomes.

Multivariable conditional logistic regression with covariates including age, sex, BMI, physical activity (using PASE 39), isokinetic quadriceps strength, smoking status, depressive symptoms (using CES-D scale), self-reported race, clinic site, diabetes and knee injury history was performed to examine the association of baseline AR levels with incident OA outcomes up to 60 months. Sensitivity analysis limiting incidence to 30-month follow-up was also performed.

Results: There were similar numbers with incident x-ray OA and incident symptomatic OA (Table 1). No associations of baseline AR levels with 60-month outcomes were noted (figures 1a and 1b). However, we found a significant association between the AR sum (AR C17:0 through AR C25:0) levels and radiographic OA but not symptomatic OA at 30 months (Table 2). For each AR homologue, high levels protected against later radiographic OA (Table 2).

Conclusion: AR levels were not associated with incident OA up to 60 months; however, we found a significant association between AR sum and radiographic knee OA at 30 months. Our data suggests that increased whole grain fiber intake may lower the risk of OA. More evidence is necessary to clarify the association between fiber intake and OA outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Zertuche, None; G. Rabasa, None; A. Lichtenstein, None; N. Matthan, None; M. Nevitt, None; J. Torner, None; C. Lewis, None; D. Misra, None; D. Felson, None.

To cite this abstract in AMA style:

Zertuche J, Rabasa G, Lichtenstein A, Matthan N, Nevitt M, Torner J, Lewis C, Misra D, Felson D. Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/alkylresorcinol-a-biomarker-for-whole-grain-intake-and-its-association-with-osteoarthritis-the-most-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alkylresorcinol-a-biomarker-for-whole-grain-intake-and-its-association-with-osteoarthritis-the-most-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology